Renalytix AI plc (RENX) - Total Liabilities

Latest as of December 2024: GBX12.81 Million GBX ≈ $1.56K USD

Based on the latest financial reports, Renalytix AI plc (RENX) has total liabilities worth GBX12.81 Million GBX (≈ $1.56K USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore RENX long-term investments to assets to see how much of total assets are deployed in long-term investments.

Renalytix AI plc - Total Liabilities Trend (2012–2025)

This chart illustrates how Renalytix AI plc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Renalytix AI plc asset portfolio.

Renalytix AI plc Competitors by Total Liabilities

The table below lists competitors of Renalytix AI plc ranked by their total liabilities.

Company Country Total Liabilities
GAMES BOX S.A. ZY-10
F:ZN6
Germany €294.72K
Quintegra Solutions Limited
NSE:QUINTEGRA
India Rs142.76 Million
Hercules Site Services PLC
LSE:HERC
UK GBX28.70 Million
Cardiff Property PLC
LSE:CDFF
UK GBX1.05 Million
Duearity AB
ST:DEAR
Sweden Skr22.38 Million
Challenger Energy Group PLC
LSE:CEG
UK GBX13.66 Million
Global PVQ SE
HM:QCE
Germany €1.18 Billion

Liability Composition Analysis (2012–2025)

This chart breaks down Renalytix AI plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Renalytix AI plc to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.43 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -9.36 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.12 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Renalytix AI plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Renalytix AI plc (2012–2025)

The table below shows the annual total liabilities of Renalytix AI plc from 2012 to 2025.

Year Total Liabilities Change
2025-06-30 GBX13.10 Million
≈ $1.59K
-17.22%
2024-06-30 GBX15.83 Million
≈ $1.93K
-99.97%
2023-12-31 GBX54.50 Billion
≈ $6.63 Million
+230225.83%
2023-06-30 GBX23.66 Million
≈ $2.88K
+17.79%
2022-06-30 GBX20.09 Million
≈ $2.44K
+168.71%
2021-06-30 GBX7.48 Million
≈ $909.61
+40.10%
2020-06-30 GBX5.34 Million
≈ $649.24
+606.75%
2019-06-30 GBX755.00K
≈ $91.86
+1043.68%
2018-06-30 GBX66.02K
≈ $8.03
-100.00%
2016-12-31 GBX41.52 Billion
≈ $5.05 Million
+5.56%
2015-12-31 GBX39.33 Billion
≈ $4.79 Million
-3.76%
2014-12-31 GBX40.87 Billion
≈ $4.97 Million
-3.33%
2013-12-31 GBX42.28 Billion
≈ $5.14 Million
+6.03%
2012-12-31 GBX39.87 Billion
≈ $4.85 Million
--

About Renalytix AI plc

LSE:RENX UK Health Information Services
Market Cap
$332.33K
GBX2.73 Billion GBX
Market Cap Rank
#31198 Global
#978 in UK
Share Price
GBX6.25
Change (1 day)
+1.63%
52-Week Range
GBX1.80 - GBX10.75
All Time High
GBX1220.00
About

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more